LPL Financial
MRSN

LPL Financial’s Mersana Therapeutics MRSN Stock Holding History

LPL Financial’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,068
Closed -$178K – 4989
2023
Q4 		$178K Buy
+3,068
New +$123K ﹤0.01% 4424

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

LPL Financial's MRSN Position: Q1 2024 in Review

LPL Financial sold out of Mersana Therapeutics (MRSN) in Q1 2024, closing a stake of 3,068 shares — an estimated $178K sold.

LPL Financial first reported a position in MRSN in Q4 2023 and held it in 1 quarter. The position peaked at $178K in Q4 2023. 122 funds tracked by Wall St. Rank hold MRSN as of Q1 2024.

  • LPL Financial reported no remaining Mersana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • LPL Financial sold 3,068 Mersana Therapeutics shares in Q1 2024, an estimated $178K.
  • LPL Financial first reported a position in Mersana Therapeutics in Q4 2023 and held it in 1 quarter.
  • LPL Financial's Mersana Therapeutics position peaked at $178K in Q4 2023.
  • 122 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2024.

Based on LPL Financial's 13F filing for Q1 2024, filed 10 May 2024.